Surgery Partners Q1 Earnings: A Test of Resilience Amid Growth

BRENTWOOD, TN – April 17, 2026 – As Surgery Partners, Inc. (NASDAQ:SGRY) prepares to release its first quarter 2026 financial results on May 5, investors and industry analysts are keenly awaiting a crucial update. The announcement, a standard precursor to a public company's quarterly performance review, carries significant weight this time around, serving as a key barometer for both the company's trajectory and the health of the broader outpatient surgical market.

The Brentwood-based operator of short-stay surgical facilities will hold a conference call at 8:30 a.m. Eastern Time following the pre-market release. The discussion is expected to provide critical insights into the company's operational health after a challenging end to 2025 and offer a clearer picture of its path forward in a dynamic healthcare landscape.

A Look Back at a Mixed 2025

To understand what's at stake in the upcoming report, it's essential to look at the company's recent performance. Surgery Partners closed 2025 with a mixed report that highlighted both the opportunities and the obstacles in its path. For the full year, the company posted a 6.2% increase in revenue to $3.3 billion, demonstrating continued top-line growth. However, its full-year Adjusted EBITDA of $526.2 million fell below initial expectations, reflecting margin compression of 40 basis points.

The fourth quarter of 2025 encapsulated this dichotomy. While revenue grew 2.4% year-over-year to $885.0 million, surpassing analyst estimates, Adjusted EBITDA declined 4.2% to $156.9 million. More pointedly, adjusted earnings per share came in at just $0.12, a significant miss compared to analyst forecasts. The company attributed these shortfalls to "significant and unanticipated headwinds" in the second half of the year, particularly within three of its surgical hospital markets. These challenges included unfavorable shifts in payer mix, with a lower-than-expected volume of commercially insured patients, and unexpected physician transitions.

Investors will be scrutinizing the Q1 2026 results for signs that these issues were temporary and have been successfully addressed. A key metric to watch will be same-facility revenue and case volume. In Q4 2025, same-facility revenues grew 3.5%, a slowdown from the 5.2% growth seen in Q1 2025. A return to stronger same-facility growth would signal that the core business remains robust.

Navigating Industry Tailwinds and Headwinds

Surgery Partners operates at the center of a major structural shift in healthcare: the migration of surgical procedures from traditional inpatient hospitals to more cost-effective and convenient ambulatory surgery centers (ASCs). This trend is a powerful tailwind, fueled by technological advancements in minimally invasive surgery, strong patient preference, and incentives from payers like Medicare and commercial insurers.

The company has been a major beneficiary of this shift, particularly in high-growth specialties. Orthopedics, for instance, has been a standout performer, with total joint replacement procedures growing 19% year-to-date in 2025. This strategic focus on higher-acuity cases is a core part of the company's value proposition.

However, the company is not immune to the macroeconomic and industry-specific pressures affecting the entire healthcare sector. Persistent labor shortages and rising wage inflation continue to challenge profit margins across the industry. Surgery Partners specifically noted higher labor and anesthesia costs as a factor in its 2025 performance. Furthermore, rising interest rates impact the cost of capital for a company that relies on acquisitions for growth and carries a significant debt load of $2.6 billion. The upcoming report will provide an update on how effectively management is navigating these inflationary pressures and managing its balance sheet.

A Blueprint for Growth: Acquisitions and Strategic Execution

Despite the recent headwinds, Surgery Partners has not wavered from its aggressive growth strategy. The company's model is built on a dual engine of acquiring existing facilities and developing new ones (de novos), all while fostering strong partnerships with physicians.

In 2025, the company deployed $182 million toward acquisitions and successfully launched eight de novo centers. Looking ahead, it has signaled its intent to deploy at least $200 million for acquisitions in 2026. A recent transaction added eight ambulatory centers to its portfolio of over 200 locations across 30 states. This expansionary strategy was further bolstered by a December 2025 joint venture with Baylor Scott & White Health, aimed at expanding access to care in key markets.

Beyond M&A, the company is focused on operational execution. After the Q4 2025 earnings miss, management emphasized a renewed focus on "tightening execution" to strengthen performance. The upcoming earnings call will be an opportunity for executives to detail the specific steps being taken to improve payer mix dynamics, stabilize physician networks in challenged markets, and drive efficiencies. Investors will also look for updates on the company's $200 million share repurchase program, authorized in February 2026, as a signal of the board's confidence in the company's intrinsic value.

What Investors Will Be Watching

When Surgery Partners executives take the virtual stage on May 5, their commentary will be as important as the numbers themselves. Wall Street, which holds a consensus "Buy" rating on the stock, will be listening for reassurance. The company's 2026 guidance, which projects revenues between $3.35 billion and $3.45 billion and Adjusted EBITDA of at least $530 million, sets a clear benchmark.

The first quarter report will be the first major data point to measure progress against that guidance. Key questions will revolve around margin recovery, the stabilization of case volume and payer mix in the previously troubled hospital markets, and the performance of recent acquisitions. The report will ultimately serve as a pulse check on whether the challenges of late 2025 were a temporary anomaly or the start of a more persistent trend, and whether the company's aggressive growth strategy can deliver the profitable returns that investors expect in the burgeoning short-stay surgical sector.